ONYX-I: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Asian Adults with Genotype 1b Chronic Hepatitis C Virus (HCV) Infection - A Randomized, Double-Blind, Placebo-Controlled Study
单位：[1]Peking Univ, Peoples Hosp, Beijing, Peoples R China[2]Nanfang Hosp, Guangzhou, Guangdong, Peoples R China[3]AbbVie Inc, N Chicago, IL USA[4]Pusan Natl Univ, Dept Internal Med, Coll Med, Busan, South Korea[5]Pusan Natl Univ Hosp, Med Res Inst, Busan, South Korea[6]Taipei Vet Gen Hosp, Taipei, Taiwan[7]Capital Med Univ, Beijing Youan Hosp, Beijing, Peoples R China[8]Pusan Natl Univ, Yangsan Hosp, Yangsan, South Korea[9]Capital Med Univ, Beijing Di Tan Hosp, Beijing, Peoples R China[10]Jiangsu Prov Hosp, Nanjing, Jiangsu, Peoples R China江苏省人民医院[11]Capital Med Univ, Beijing Friendship Hosp, Beijing, Peoples R China首都医科大学附属北京友谊医院[12]Kaohsiung Med Univ, Kaohsiung, Taiwan
第一作者单位：[1]Peking Univ, Peoples Hosp, Beijing, Peoples R China
推荐引用方式(GB/T 7714)：
Wei Lai,Hou Jinlin,Luo Yan,et al.ONYX-I: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Asian Adults with Genotype 1b Chronic Hepatitis C Virus (HCV) Infection - A Randomized, Double-Blind, Placebo-Controlled Study[J].HEPATOLOGY.2016,64:432A-433A.
APA：
Wei, Lai,Hou, Jinlin,Luo, Yan,Heo, Jeong,Chu, Chi-Jen...&Chuang, Wan-Long.(2016).ONYX-I: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Asian Adults with Genotype 1b Chronic Hepatitis C Virus (HCV) Infection - A Randomized, Double-Blind, Placebo-Controlled Study.HEPATOLOGY,64,
MLA：
Wei, Lai,et al."ONYX-I: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Asian Adults with Genotype 1b Chronic Hepatitis C Virus (HCV) Infection - A Randomized, Double-Blind, Placebo-Controlled Study".HEPATOLOGY 64.(2016):432A-433A
医学